Goals This pilot research investigated the accuracy of onsite immunoassay urinalysis of illicit drug use in 42 outpatients with co-occurring material use disorders and serious mental illness. spectrometry (GC-MS) analyses. Results Agreement between immunoassay and GC-MS CCT137690 was calculated. Agreement was high with 98% agreement for amphetamine methamphetamine opiate and marijuana. Agreement for cocaine was 93%. Conclusions Results of this pilot study support the use of onsite immunoassay screening cups as an assessment and outcome measure in adults with serious mental illness. Scientific Significance Data suggest that onsite urinalysis screenings may be a helpful assessment tool for measuring clinical and research outcomes. = 181). The first 42 participants were selected for this sub-study. Participants were recruited from multiple clinical settings (including an urban drop-in center; a court-mandated drug treatment program a typical outpatient addiction treatment program and urban and suburban community mental health centers) within a large community mental health and addiction treatment agency. All psychiatric and material use disorders were made using the MINI neuropsychiatric interview (9). CCT137690 All diagnostic interviews were conducted at study enrollment by trained research staff under the supervision of the first and last author. Forty-two psychostimulant-dependent adults (= 31 Rabbit Polyclonal to FMN2. 74 males = 11 26 females) aged 25-60 years (= 43.9 SD = 8.9) were the participants. They were 55% (= 23) Caucasian 26 (= 11) African-American and 19% (= 8) other ethnicities. Rates of current material dependence diagnoses were 95% (= 41) cocaine 29 (= 12) methamphetamine 24 (= 10) amphetamine 15 (= 6) marijuana 24 (= 10) opiate and 57% (= 24) alcohol. All participants carried an SMI diagnosis including recurring major depressive disorder (= 8 19 bipolar disorder (= 13 31 schizophrenia (= 4 10 or schizoaffective disorder (= 17 40 Sixty-three percent (= 26) of the sample reported that these were presently taking psychotropic medicines with 36% (= 15) acquiring multiple psychotropic medicines. Self-reported psychotropic medicines included atypical antipsychotics (= 20 47 selective serotonin reuptake inhibitors (= 9 21 selective serotonin-neuroepinephrine reuptake inhibitors (= 2 5 antiseizure/disposition stabilizers (= 6 14 lithium (= 1 CCT137690 2 anxiolytics (= 2 5 methadone (= 1 2 and prescription CCT137690 opiates (= 2 5 Each participant received up to 40 immunoassay urinalyses within their participation in the mother or father study. Urine examples had been gathered and screened for drug use using Integrated EZ Split Key? Cup (Innovacon Inc. San Diego CA USA). This device includes an internal thermometer used to assess the heat of the sample. This onsite testing device employs an immunoassay for drugs and metabolites using the following cutoff levels: amphetamines (d-amphetamine = 1000 ng/mL) methamphetamine (d-methamphetamine = 1000 ng/mL) cocaine (benzoylecgonine = 300 ng/mL) opiates (morphine = 2000 ng/mL) and tetrahydrocannabinol (THC) (THC-COOH = 50 ng/mL). The procedure for conducting these onsite immunoassays involved the participant providing a urine sample in the testing cup. Samples CCT137690 were immediately provided to trained research assistants who verified their acceptable heat (90-100°F) of the urine using an internal thermometer. If the sample temperatures were abnormally high or low they were discarded and another sample with an acceptable temperature was gathered. The research assistant then inserted a “key” into the testing device to begin the immunoassay test. After 5 min the research assistant decided the test results by examining the presence of one (positive test) or two lines (unfavorable test) on each drug-testing strip displayed on the side of the testing device. These results were then recorded. No adulterant assessments were conducted as part of immunoassays. One immunoassay from each participant was randomly selected for confirmatory urinalysis. These samples were prepared for transportation in sealed packaging and sent through overnight courier to Redwood Toxicology (redwoodtoxicology.com) for GC-MS. The cutoff levels of detection for GC-MS were identical to immunoassays. Creatinine levels of each GC-MS test were calculated. Contract between immunoassay and GC-MS was evaluated for each medication of mistreatment (accurate negatives + accurate positives/total variety of examples). The magnitude of contract beyond.